Metabolic profiling in new on-set non-ischemic dilated cardiomyopathy

Dilated cardiomyopathy is known as the most common cardiomyopathy with no therapy directly targeted the pathogenesis. The metabolic is a promising tool for better understanding of the difference in metabolites between health and disease and offering therapeutic targets, but the understanding of the specific metabolic processes distinguishing new on-set DCM from normal individuals remains insufficient.

To investigate the targeted blood metabolic profiling distinctions between new on-set Dilated Cardiomyopathy (DCM) and normal group.

We analyzed 231 plasma metabolites by liquid chromatography ⁄ mass spectroscopy and gas chromatography ⁄ mass spectroscopy in 48 patients with new on-set DCM(the duration of DCM diagnosis was less than 6 month before enrollment) and 48 age-, sex- and body mass index-matched normal controls.

Twenty-four metabolites were significantly different between DCM and control individuals when adjusted by sex, age and smoking [false discovery rate (FDR) < 0.05]. Plasma levels of guanidinoacetate, hypoxanthin were reduced while levels of 6-methyladenosine, 1-methyladenosine and others were increased in patients with DCM when compared to controls (figure 1), while Taurine, L-kynurenine and Methylmalonate were the most significant metabolites between the two groups (figure 2) .

Metabolic processes were strongly enhanced in DCM and may be used to distinguish new on-set DCM from normal individuals. And it identififies biologically active metabolites that could serve as markers of New-onset DCM and impart protective or harmful effects on cardiac structure and function.